| Peer-Reviewed

Current Thinking on Malignant Salivary Gland Neoplasms

Received: 14 July 2013     Published: 10 August 2013
Views:       Downloads:
Abstract

Malignant salivary gland neoplasms are rare, representing approximately 3% to 7% of all head and neck cancers. Contrasting from the more common mucosal head and neck cancers, which, in general, are ascribed to excessive tobacco, alcohol use, and more recently to viral infection, specific carcinogenic factors for malignant salivary gland growths have not been as clearly identified. Histologically, they represent a heterogeneous group of tumors. Forty histologic types of epithelial tumors of the salivary glands have been reported; some are exceedingly rare and may be the topic of only a few case reports. Salivary tumors can arise in the major salivary glands or in one of the minor salivary glands (predominantly mucus secreting glands), which are distributed throughout the upper aerodigestive. Most patients who develop malignant salivary gland tumors are in the sixth or seventh decade of life. FNA should be considered as part of the diagnostic evaluation but due to its varying sensitivities and specificities imaging modalities such as ultrasound, CT scans, and MRI should also be used as diagnostic adjuncts. Surgery is the primary modality for management of these tumors, nontraditional surgical approaches and instrumentation, as well as facial nerve monitoring, can be selectively utilized to try and decrease the morbidity associated with these surgical procedures. Adjuvant treatment is primarily achieved with radiation therapy. Chemotherapy continues to have a palliative role in the management of salivary gland tumors; however, research in this field is trying to identify a therapeutic role for chemotherapy in order to improve overall survival.

Published in Journal of Cancer Treatment and Research (Volume 1, Issue 1)
DOI 10.11648/j.jctr.20130101.12
Page(s) 8-24
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2013. Published by Science Publishing Group

Keywords

Salivary Gland Tumors, Epidemiology of Salivary Gland Tumors, Types of Salivary Gland Tumors, Diagnosis and Treatment of Salivary Gland Tumors

References
[1] Speight, P.M. and A.W. Barrett, Salivary gland tumours. Oral diseases, 2002. 8(5): p. 229-40.
[2] van der Laan, B.F., et al., Radiation-induced tumours of the head and neck. The Journal of laryngology and otology, 1995. 109(4): p. 346-9.
[3] Scanlon, E.F. and S.F. Sener, Head and neck neoplasia following irradiation for benign conditions. Comprehensive therapy, 1981. 7(12): p. 59-64.
[4] Belsky, J.L., et al., Salivary gland neoplasms following atomic radiation: additional cases and reanalysis of combined data in a fixed population, 1957-1970. Cancer, 1975. 35(2): p. 555-9.
[5] Horn-Ross, P.L., B.M. Ljung, and M. Morrow, Environmental factors and the risk of salivary gland cancer. Epidemiology, 1997. 8(4): p. 414-9.
[6] Spitz, M.R., et al., Risk factors for major salivary gland carcinoma. A case-comparison study. Cancer, 1984. 54(9): p. 1854-9.
[7] Muscat, J.E. and E.L. Wynder, A case/control study of risk factors for major salivary gland cancer. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1998. 118(2): p. 195-8.
[8] Saku, T., et al., Salivary gland tumors among atomic bomb survivors, 1950-1987. Cancer, 1997. 79(8): p. 1465-75.
[9] Leclerc, A., et al., Sinonasal cancer and wood dust exposure: results from a case-control study. American journal of epidemiology, 1994. 140(4): p. 340-9.
[10] Bonneterre, V., et al., Sino-nasal cancer and exposure to leather dust. Occupational medicine, 2007. 57(6): p. 438-43.
[11] Spiro, R.H., Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head & neck surgery, 1986. 8(3): p. 177-84.
[12] Wahlberg, P., et al., Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients. Oral oncology, 2002. 38(7): p. 706-13.
[13] Lalwani, A.K., Current Diangosis and Treatment in Otolaryngology Head and Neck Surgery, ed. M. Anil K. Lalwani2008: The McGraw-Hill Companies.
[14] Harrison, L.B., Head and Neck Cancer A multidisciplinary Approach. Third ed, ed. H. Louis B, Roy B. Sessions, Waun Ki Hong. Vol. 1. 2009, Philadelphia: Lippincott Wialliams and Wilkings. 1002.
[15] Theriault, C. and P.J. Fitzpatrick, Malignant parotid tumors. Prognostic factors and optimum treatment. American journal of clinical oncology, 1986. 9(6): p. 510-6.
[16] Oncology, N.C.C.N.C.P.G.i. Head and Neck Cancer. 2011 [cited 2011 2011]; Version2.2011:[
[17] Brandwein, M.S., et al., Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta oto-laryngologica, 2002. 122(7): p. 758-64.
[18] Barnes, L., Everson, JW, Reichart, P, et al., World Health Organization classification of tumours: pathology and genetics of the head and neck. IARC Press, 2005.
[19] Rapidis, A.D., et al., Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. Oral oncology, 2007. 43(2): p. 130-6.
[20] Seifert, G., Sobin,l.h., Histological typing of salivary gland tumours. WHO international histological classification of tumour, 1991: Berlin, New York, Heidelberg.
[21] Batsakis, J.G., et al., Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. The Journal of laryngology and otology, 1989. 103(10): p. 939-44.
[22] Guzzo, M., et al., Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Annals of surgical oncology, 2002. 9(7): p. 688-95.
[23] Goode, R.K., P.L. Auclair, and G.L. Ellis, Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer, 1998. 82(7): p. 1217-24.
[24] Brandwein, M.S., et al., Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. The American journal of surgical pathology, 2001. 25(7): p. 835-45.
[25] Evans, H.L., Mucoepidermoid carcinoma of salivary glands: a study of 69 cases with special attention to histologic grading. American journal of clinical pathology, 1984. 81(6): p. 696-701.
[26] Eveson, J.W. and R.A. Cawson, Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. The Journal of pathology, 1985. 146(1): p. 51-8.
[27] Goode, R., El-Naggar, AK., Mucoepidermoid carcinoma. Wolrd Health Organization classification of tumour. Pathology and genetics of head and neck tumours, ed. E. In BarnesL, JW, Reichart P, Sidransky D.2005: Lyon.
[28] Ellis, G., Auclair, PL, Atlas of Tumor Pathology, Tumors of the Salivary Glands, series 3, fascicle 7, A.F.I.o. Pathology, Editor 1996: Washington DC. p. 353-355.
[29] Westra, W.H., The surgical pathology of salivary gland neoplasms. Otolaryngologic clinics of North America, 1999. 32(5): p. 919-43.
[30] Spiro, R.H., et al., Mucoepidermoid carcinoma of salivary gland origin. A clinicopathologic study of 367 cases. American journal of surgery, 1978. 136(4): p. 461-8.
[31] Healey, W.V., K.H. Perzin, and L. Smith, Mucoepidermoid carcinoma of salivary gland origin. Classification, clinical-pathologic correlation, and results of treatment. Cancer, 1970. 26(2): p. 368-88.
[32] Hamper, K., et al., Mucoepidermoid tumors of the salivary glands. Correlation of cytophotometrical data and prognosis. Cancer, 1989. 63(4): p. 708-17.
[33] Clode, A.L., et al., Mucoepidermoid carcinoma of the salivary glands: a reappraisal of the influence of tumor differentiation on prognosis. Journal of surgical oncology, 1991. 46(2): p. 100-6.
[34] Waldron, C.A., S.K. el-Mofty, and D.R. Gnepp, Tumors of the intraoral minor salivary glands: a demographic and histologic study of 426 cases. Oral surgery, oral medicine, and oral pathology, 1988. 66(3): p. 323-33.
[35] Aro, K., I. Leivo, and A.A. Makitie, Management and outcome of patients with mucoepidermoid carcinoma of major salivary gland origin: a single institution's 30-year experience. The Laryngoscope, 2008. 118(2): p. 258-62.
[36] Thompson, L.D., Salivary gland acinic cell carcinoma. Ear, nose, & throat journal, 2010. 89(11): p. 530-2.
[37] Al-Zaher, N., et al., Acinic cell carcinoma of the salivary glands: a literature review. Hematology/oncology and stem cell therapy, 2009. 2(1): p. 259-64.
[38] Hoffman, H.T., et al., National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Head & neck, 1999. 21(4): p. 297-309.
[39] Spafford, P.D., D.R. Mintz, and J. Hay, Acinic cell carcinoma of the parotid gland: review and management. The Journal of otolaryngology, 1991. 20(4): p. 262-6.
[40] Spiro, R.H., A.G. Huvos, and E.W. Strong, Acinic cell carcinoma of salivary origin. A clinicopathologic study of 67 cases. Cancer, 1978. 41(3): p. 924-35.
[41] Simpson, R.H., Classification of salivary gland tumours--a brief histopathological review. Histology and histopathology, 1995. 10(3): p. 737-46.
[42] Slater, L.J., Acinic cell carcinoma and PAS-positive granules. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 1998. 86(5): p. 507-8.
[43] Perzin, K.H. and V.A. LiVolsi, Acinic cell carcinomas arising in salivary glands: a clinicopathologic study. Cancer, 1979. 44(4): p. 1434-57.
[44] Lewis, J.E., K.D. Olsen, and L.H. Weiland, Acinic cell carcinoma. Clinicopathologic review. Cancer, 1991. 67(1): p. 172-9.
[45] Napier, S.S., B.T. Herron, and B.M. Herron, Acinic cell carcinoma in Northern Ireland: a 10-year review. The British journal of oral & maxillofacial surgery, 1995. 33(3): p. 145-8.
[46] Spiro, R.H. and A.G. Huvos, Stage means more than grade in adenoid cystic carcinoma. American journal of surgery, 1992. 164(6): p. 623-8.
[47] Bradley, P.J., Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolarngol Head Neck Surg. Vol. 12. 2004: Lippincott Williams and Wilkins.
[48] Martinez-Rodriguez, N., et al., Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: A meta-analytic study. Medicina oral, patologia oral y cirugia bucal, 2011.
[49] Szanto, P.A., et al., Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer, 1984. 54(6): p. 1062-9.
[50] Kumar, P.P., et al., Intracranial skip metastasis from parotid and facial skin tumors: mechanism, diagnosis, and treatment. Journal of the National Medical Association, 1993. 85(5): p. 369-74.
[51] Gnepp, D.R., Malignant mixed tumors of the salivary glands: a review. Pathology annual, 1993. 28 Pt 1: p. 279-328.
[52] Nouraei, S.A., et al., Carcinoma ex benign pleomorphic adenoma of the parotid gland. Plastic and reconstructive surgery, 2005. 116(5): p. 1206-13.
[53] Zbaren, P., et al., Carcinoma ex pleomorphic adenoma: diagnostic difficulty and outcome. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2008. 138(5): p. 601-5.
[54] Damm, D.D. and J.E. Fantasia, Large palatal mass. Carcinoma ex-pleomorphic adenoma. General dentistry, 2001. 49(6): p. 574, 658.
[55] Yoshihara, T., et al., Carcinoma ex pleomorphic adenoma of the soft palate. The Journal of laryngology and otology, 1995. 109(3): p. 240-3.
[56] Antony, J., et al., Carcinoma ex Pleomorphic Adenoma: A Comprehensive Review of Clinical, Pathological and Molecular Data. Head and neck pathology, 2011.
[57] Tortoledo, M.E., M.A. Luna, and J.G. Batsakis, Carcinomas ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Archives of otolaryngology, 1984. 110(3): p. 172-6.
[58] Touquet, R., I.J. Mackenzie, and J.A. Carruth, Management of the parotid pleomorphic adenoma, the problem of exposing tumour tissue at operation. The logical pursuit of treatment policies. The British journal of oral & maxillofacial surgery, 1990. 28(6): p. 404-8.
[59] Kwon, M.Y. and M. Gu, True malignant mixed tumor (carcinosarcoma) of parotid gland with unusual mesenchymal component: a case report and review of the literature. Archives of pathology & laboratory medicine, 2001. 125(6): p. 812-5.
[60] Olsen, K.D. and J.E. Lewis, Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head & neck, 2001. 23(9): p. 705-12.
[61] Luers, J.C., et al., Carcinoma ex pleomorphic adenoma of the parotid gland. Study and implications for diagnostics and therapy. Acta oncologica, 2009. 48(1): p. 132-6.
[62] Nicol, K.K. and S.S. Iskandar, Lobular carcinoma of the breast metastatic to the oral cavity mimicking polymorphous low-grade adenocarcinoma of the minor salivary glands. Archives of pathology & laboratory medicine, 2000. 124(1): p. 157-9.
[63] Batsakis, J.G., et al., Adenocarcinomas of the oral cavity: a clinicopathologic study of terminal duct carcinomas. The Journal of laryngology and otology, 1983. 97(9): p. 825-35.
[64] Freedman, P.D. and H. Lumerman, Lobular carcinoma of intraoral minor salivary gland origin. Report of twelve cases. Oral surgery, oral medicine, and oral pathology, 1983. 56(2): p. 157-66.
[65] Pogodzinski, M.S., et al., Retrospective study and review of polymorphous low-grade adenocarcinoma. The Laryngoscope, 2006. 116(12): p. 2145-9.
[66] Zarbo, R.J., Salivary gland neoplasia: a review for the practicing pathologist. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2002. 15(3): p. 298-323.
[67] Adornato, M.C., K. Penna, and M. Vinoski, Polymorphous low-grade adenocarcinoma of the oral cavity. The New York state dental journal, 2000. 66(5): p. 28-32.
[68] Vincent, S.D., H.L. Hammond, and M.W. Finkelstein, Clinical and therapeutic features of polymorphous low-grade adenocarcinoma. Oral surgery, oral medicine, and oral pathology, 1994. 77(1): p. 41-7.
[69] Evans, H.L. and M.A. Luna, Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. The American journal of surgical pathology, 2000. 24(10): p. 1319-28.
[70] Seethala, R.R., et al., Polymorphous low-grade adenocarcinoma: the University of Pittsburgh experience. Archives of otolaryngology--head & neck surgery, 2010. 136(4): p. 385-92.
[71] Simpson, R.H., et al., Polymorphous low-grade adenocarcinoma of the salivary glands with transformation to high-grade carcinoma. Histopathology, 2002. 41(3): p. 250-9.
[72] Kinnera, V.S., et al., Salivary duct carcinoma of parotid gland. Journal of oral and maxillofacial pathology : JOMFP, 2009. 13(2): p. 85-8.
[73] Lewis, J.E., et al., Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer, 1996. 77(2): p. 223-30.
[74] Brandwein, M.S., et al., Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts). A clinicopathologic and immunohistochemical study of 12 cases. Cancer, 1990. 65(10): p. 2307-14.
[75] Chen, K.T. and G.R. Hafez, Infiltrating salivary duct carcinoma. A clinicopathologic study of five cases. Archives of otolaryngology, 1981. 107(1): p. 37-9.
[76] Delgado, R., F. Vuitch, and J. Albores-Saavedra, Salivary duct carcinoma. Cancer, 1993. 72(5): p. 1503-12.
[77] Colmenero Ruiz, C., M. Patron Romero, and M. Martin Perez, Salivary duct carcinoma: a report of nine cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1993. 51(6): p. 641-6.
[78] Simpson, R.H., et al., Salivary duct adenocarcinoma. Histopathology, 1991. 18(3): p. 229-35.
[79] Auclair PL, E.C.A.P., Ellis CL. , Adenocarcinoma, not otherwise specified. Surgical Pathology of the Salivary Glands. , ed. A.P. Ellis GL, Gnepp DR, eds.1991, Philadelphia, Pa: WB Saunders Co.
[80] van der Wal, J.E., et al., Parotid gland tumors: histologic reevaluation and reclassification of 478 cases. Head & neck, 1998. 20(3): p. 204-7.
[81] O'Brien, C.J., V.B. Malka, and M. Mijailovic, Evaluation of 242 consecutive parotidectomies performed for benign and malignant disease. The Australian and New Zealand journal of surgery, 1993. 63(11): p. 870-7.
[82] O'Hara, J., et al., Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland-A review of current recommendations. Head & neck, 2010.
[83] Guillamondegui, O.M., Salivary gland cancers, surgery, and irradiation therapy. Archives of otolaryngology, 1982. 108(11): p. 709.
[84] Lee, S., et al., Primary squamous cell carcinoma of the parotid gland. American journal of otolaryngology, 2001. 22(6): p. 400-6.
[85] Batsakis, J.G., et al., Primary squamous cell carcinoma of the parotid gland. Archives of otolaryngology, 1976. 102(6): p. 355-7.
[86] Ying, Y.L., J.T. Johnson, and E.N. Myers, Squamous cell carcinoma of the parotid gland. Head & neck, 2006. 28(7): p. 626-32.
[87] Marshak, G. and O. Leitner, Cytokeratin polypeptides in normal and metaplastic human salivary gland epithelia. Journal of oral pathology, 1987. 16(9): p. 442-9.
[88] Okura, M., et al., Expression of S-100 protein and glial fibrillary acidic protein in cultured submandibular gland epithelial cells and salivary gland tissues. Histogenetic implication for salivary gland tumors. The American journal of pathology, 1996. 148(5): p. 1709-16.
[89] Draeger, A., et al., Cytokeratins, smooth muscle actin and vimentin in human normal salivary gland and pleomorphic adenomas. Immunohistochemical studies with particular reference to myoepithelial and basal cells. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 1991. 99(5): p. 405-15.
[90] He, H., et al., A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland. Journal of cancer research and clinical oncology, 2009. 135(10): p. 1315-21.
[91] Holst, V.A., et al., KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 1999. 12(10): p. 956-60.
[92] Tetsu, O., et al., Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia, 2010. 12(9): p. 708-17.
[93] Jeng, Y.M., C.Y. Lin, and H.C. Hsu, Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer letters, 2000. 154(1): p. 107-11.
[94] Curran, A.E., et al., Distinctive pattern of glial fibrillary acidic protein immunoreactivity useful in distinguishing fragmented pleomorphic adenoma, canalicular adenoma and polymorphous low grade adenocarcinoma of minor salivary glands. Head and neck pathology, 2007. 1(1): p. 27-32.
[95] Curran, A.E., et al., Polymorphous low-grade adenocarcinoma versus pleomorphic adenoma of minor salivary glands: resolution of a diagnostic dilemma by immunohistochemical analysis with glial fibrillary acidic protein. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2001. 91(2): p. 194-9.
[96] Scianna, J.M. and G.J. Petruzzelli, Contemporary management of tumors of the salivary glands. Current oncology reports, 2007. 9(2): p. 134-8.
[97] Day, T.A., et al., Salivary gland neoplasms. Current treatment options in oncology, 2004. 5(1): p. 11-26.
[98] Gates, G.A., Current concepts in otolaryngology: malignant neoplasms of the minor salivary glands. The New England journal of medicine, 1982. 306(12): p. 718-22.
[99] Wong, D.S. and G.K. Li, The role of fine-needle aspiration cytology in the management of parotid tumors: a critical clinical appraisal. Head & neck, 2000. 22(5): p. 469-73.
[100] Sismanis, A., et al., Diagnosis of salivary gland tumors by fine needle aspiration biopsy. Head & neck surgery, 1981. 3(6): p. 482-9.
[101] Kechagias, N., et al., Fine-needle aspiration cytology of salivary gland tumours: a 10-year retrospective analysis. Oral and maxillofacial surgery, 2011.
[102] Cohen, E.G., et al., Fine-needle aspiration biopsy of salivary gland lesions in a selected patient population. Archives of otolaryngology--head & neck surgery, 2004. 130(6): p. 773-8.
[103] Jayaram, N., et al., The value of fine-needle aspiration biopsy in the cytodiagnosis of salivary gland lesions. Diagnostic cytopathology, 1989. 5(4): p. 349-54.
[104] Cardillo, M.R., Salivary gland masses: the diagnostic value of fine-needle aspiration cytology. Archives d'anatomie et de cytologie pathologiques, 1990. 38(1-2): p. 26-32.
[105] Megerian, C.A. and A.J. Maniglia, Parotidectomy: a ten year experience with fine needle aspiration and frozen section biopsy correlation. Ear, nose, & throat journal, 1994. 73(6): p. 377-80.
[106] Stewart, C.J., et al., Fine-needle aspiration cytology of salivary gland: a review of 341 cases. Diagnostic cytopathology, 2000. 22(3): p. 139-46.
[107] Alphs, H.H., D.W. Eisele, and W.H. Westra, The role of fine needle aspiration in the evaluation of parotid masses. Current opinion in otolaryngology & head and neck surgery, 2006. 14(2): p. 62-6.
[108] Seethala, R.R., V.A. LiVolsi, and Z.W. Baloch, Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of lesions of the parotid gland. Head & neck, 2005. 27(3): p. 217-23.
[109] Cho, H.W., et al., Sonographically guided fine-needle aspiration biopsy of major salivary gland masses: a review of 245 cases. AJR. American journal of roentgenology, 2011. 196(5): p. 1160-3.
[110] Mighell, A.J. and A.S. High, Histological identification of carcinoma in 21 gauge needle tracks after fine needle aspiration biopsy of head and neck carcinoma. Journal of clinical pathology, 1998. 51(3): p. 241-3.
[111] Moloo, Z., et al., Possible spread of bronchogenic carcinoma to the chest wall after a transthoracic fine needle aspiration biopsy. A case report. Acta cytologica, 1985. 29(2): p. 167-9.
[112] Roussel, F., J. Dalion, and M. Benozio, The risk of tumoral seeding in needle biopsies. Acta cytologica, 1989. 33(6): p. 936-9.
[113] Brennan, P.A., et al., Fine needle aspiration cytology (FNAC) of salivary gland tumours: repeat aspiration provides further information in cases with an unclear initial cytological diagnosis. The British journal of oral & maxillofacial surgery, 2010. 48(1): p. 26-9.
[114] Riley, N., R. Allison, and S. Stevenson, Fine-needle aspiration cytology in parotid masses: our experience in Canterbury, New Zealand. ANZ journal of surgery, 2005. 75(3): p. 144-6.
[115] Carrillo, J.F., et al., Diagnostic accuracy of fine needle aspiration biopsy in preoperative diagnosis of patients with parotid gland masses. Journal of surgical oncology, 2009. 100(2): p. 133-8.
[116] Cross, D.L., T.S. Gansler, and R.C. Morris, Fine needle aspiration and frozen section of salivary gland lesions. Southern medical journal, 1990. 83(3): p. 283-6.
[117] Westra, W.H., Diagnostic difficulties in the classification and grading of salivary gland tumors. International journal of radiation oncology, biology, physics, 2007. 69(2 Suppl): p. S49-51.
[118] Das, D.K., et al., Role of fine needle aspiration cytology in the diagnosis of swellings in the salivary gland regions: a study of 712 cases. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2004. 13(2): p. 95-106.
[119] Wong, D.S., Frozen section during parotid surgery revisited: efficacy of its applications and changing trend of indications. Head & neck, 2002. 24(2): p. 191-7.
[120] Iwai, H., et al., [Evaluation of frozen section diagnosis of parotid gland tumors]. Nihon Jibiinkoka Gakkai kaiho, 1999. 102(11): p. 1227-33.
[121] Carvalho, M.B., et al., Perioperative frozen section examination in parotid gland tumors. Sao Paulo medical journal = Revista paulista de medicina, 1999. 117(6): p. 233-7.
[122] Zheng, J.W., X.Y. Song, and X.G. Nie, The accuracy of clinical examination versus frozen section in the diagnosis of parotid masses. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1997. 55(1): p. 29-31; discussion 32.
[123] Arabi Mianroodi, A.A., E.A. Sigston, and N.A. Vallance, Frozen section for parotid surgery: should it become routine? ANZ journal of surgery, 2006. 76(8): p. 736-9.
[124] Edge S, B.D., Compton C, et al., AJCC Cancer Staging Manual. 7th ed2010: Springer.
[125] Lamont, J.P., et al., Prospective evaluation of office-based parotid ultrasound. Annals of surgical oncology, 2001. 8(9): p. 720-2.
[126] Corr, P., P. Cheng, and C. Metreweli, The role of ultrasound and computed tomography in the evaluation of parotid masses. Australasian radiology, 1993. 37(2): p. 195-7.
[127] Whyte, A.M. and J.V. Byrne, A comparison of computed tomography and ultrasound in the assessment of parotid masses. Clinical radiology, 1987. 38(4): p. 339-43.
[128] Jeong, H.S., et al., Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007. 48(8): p. 1237-44.
[129] Som, P.M. and H.F. Biller, High-grade malignancies of the parotid gland: identification with MR imaging. Radiology, 1989. 173(3): p. 823-6.
[130] Swartz, J.D., et al., MR imaging of parotid mass lesions: attempts at histopathologic differentiation. Journal of computer assisted tomography, 1989. 13(5): p. 789-96.
[131] Yousem, D.M., M.A. Kraut, and A.A. Chalian, Major salivary gland imaging. Radiology, 2000. 216(1): p. 19-29.
[132] Teresi, L.M., et al., Parotid masses: MR imaging. Radiology, 1987. 163(2): p. 405-9.
[133] Yabuuchi, H., et al., Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology, 2003. 226(2): p. 345-54.
[134] Nowak, B., et al., Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin. Nuclear medicine, 1999. 38(8): p. 312-8.
[135] Uchida, Y., et al., Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors. Clinical nuclear medicine, 2005. 30(3): p. 170-6.
[136] McGuirt, W.F., et al., Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. The Laryngoscope, 1995. 105(6): p. 579-84.
[137] Myers, E.N., Suen, J.Y, eds, Cancer of the Head and neck1996, Philadelphia: Saunders.
[138] Iseli, T.A., et al., Outcomes of static and dynamic facial nerve repair in head and neck cancer. The Laryngoscope, 2010. 120(3): p. 478-83.
[139] Tabb, H.G., A.N. Scalco, and S.F. Fraser, Exposure of the facial nerve in parotid surgery. (Use of the tympanomastoid fissure as a guide). The Laryngoscope, 1970. 80(4): p. 559-67.
[140] Pather, N. and M. Osman, Landmarks of the facial nerve: implications for parotidectomy. Surgical and radiologic anatomy : SRA, 2006. 28(2): p. 170-5.
[141] Beahrs, O.H. and B.F. L'Esperance, The facial nerve in parotid surgery. Journal of the American Medical Association, 1956. 162(4): p. 261-3.
[142] Toure, G. and C. Vacher, Relations of the facial nerve with the retromandibular vein: anatomic study of 132 parotid glands. Surgical and radiologic anatomy : SRA, 2010. 32(10): p. 957-61.
[143] de Ru, J.A., et al., Landmarks for parotid gland surgery. The Journal of laryngology and otology, 2001. 115(2): p. 122-5.
[144] Reid, A.P., Surgical approach to the parotid gland. Ear, nose, & throat journal, 1989. 68(2): p. 151-4.
[145] Conley, J., Search for and identification of the facial nerve. The Laryngoscope, 1978. 88(1 Pt 1): p. 172-5.
[146] Conley, J. and R.C. Hamaker, Prognosis of malignant tumors of the parotid gland with facial paralysis. Archives of otolaryngology, 1975. 101(1): p. 39-41.
[147] de Ru, J.A., et al., Preoperative determination of the location of parotid gland tumors by analysis of the position of the facial nerve. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2001. 59(5): p. 525-8; discussion 529-30.
[148] Beahrs, O.H., The surgical anatomy and technique of parotidectomy. The Surgical clinics of North America, 1977. 57(3): p. 477-93.
[149] Corlette, T.H., et al., Neck dissection of level IIb: is it really necessary? The Laryngoscope, 2005. 115(9): p. 1624-6.
[150] Schramm, V.L., Jr. and M.J. Imola, Management of nasopharyngeal salivary gland malignancy. The Laryngoscope, 2001. 111(9): p. 1533-44.
[151] Bensadoun, R.J., et al., [2003 update of Standards, Options and Recommandations for radiotherapy for patients with salivary gland malignant tumors (excluding lymphona, sarcoma and melanoma)]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003. 7(4): p. 280-95.
[152] Armstrong, J.G., et al., Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Archives of otolaryngology--head & neck surgery, 1990. 116(3): p. 290-3.
[153] Harrison, L.B., et al., Postoperative radiation therapy for major salivary gland malignancies. Journal of surgical oncology, 1990. 45(1): p. 52-5.
[154] Garden, A.S., et al., Postoperative radiotherapy for malignant tumors of the parotid gland. International journal of radiation oncology, biology, physics, 1997. 37(1): p. 79-85.
[155] Fu, K.K., et al., Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer, 1977. 40(6): p. 2882-90.
[156] Guillamondegui, O.M., et al., Aggressive surgery in treatment for parotid cancer: the role of adjunctive postoperative radiotherapy. The American journal of roentgenology, radium therapy, and nuclear medicine, 1975. 123(1): p. 49-54.
[157] Terhaard, C.H., et al., The role of radiotherapy in the treatment of malignant salivary gland tumors. International journal of radiation oncology, biology, physics, 2005. 61(1): p. 103-11.
[158] Mendenhall, W.M., et al., Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer, 2005. 103(12): p. 2544-50.
[159] Chen, A.M., et al., Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. International journal of radiation oncology, biology, physics, 2007. 67(4): p. 982-7.
[160] Garden, A.S., et al., The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. International journal of radiation oncology, biology, physics, 1995. 32(3): p. 619-26.
[161] Storey, M.R., et al., Postoperative radiotherapy for malignant tumors of the submandibular gland. International journal of radiation oncology, biology, physics, 2001. 51(4): p. 952-8.
[162] Laramore, G.E., et al., Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. International journal of radiation oncology, biology, physics, 1993. 27(2): p. 235-40.
[163] Huber, P.E., et al., Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2001. 59(2): p. 161-7.
[164] Rentschler, R., M.A. Burgess, and R. Byers, Chemotherapy of malignant major salivary gland neoplasms: a 25-year review of M. D. Anderson Hospital experience. Cancer, 1977. 40(2): p. 619-24.
[165] Licitra, L., et al., Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer, 1991. 68(9): p. 1874-7.
[166] Vermorken, J.B., et al., Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 1993. 4(9): p. 785-8.
[167] Airoldi, M., et al., Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer, 2001. 91(3): p. 541-7.
[168] Haddad, R., et al., Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral oncology, 2003. 39(7): p. 724-7.
[169] Airoldi, M., et al., Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer research, 2000. 20(5C): p. 3781-3.
[170] Cajulis, R.S., et al., Fine needle aspiration biopsy of the salivary glands. A five-year experience with emphasis on diagnostic pitfalls. Acta cytologica, 1997. 41(5): p. 1412-20.
[171] Al-Khafaji, B.M., B.R. Nestok, and R.L. Katz, Fine-needle aspiration of 154 parotid masses with histologic correlation: ten-year experience at the University of Texas M. D. Anderson Cancer Center. Cancer, 1998. 84(3): p. 153-9.
[172] Tan, L.G. and M.L. Khoo, Accuracy of fine needle aspiration cytology and frozen section histopathology for lesions of the major salivary glands. Annals of the Academy of Medicine, Singapore, 2006. 35(4): p. 242-8.
[173] Tew, S., A.G. Poole, and J. Philips, Fine-needle aspiration biopsy of parotid lesions: comparison with frozen section. The Australian and New Zealand journal of surgery, 1997. 67(7): p. 438-41.
[174] Umapathy, N., et al., Performance of parotidectomy in nonspecialist centers. Archives of otolaryngology--head & neck surgery, 2003. 129(9): p. 925-8; discussion 928.
[175] Bova, R., A. Saylor, and W.B. Coman, Parotidectomy: review of treatment and outcomes. ANZ journal of surgery, 2004. 74(7): p. 563-8.
[176] Gaillard, C., et al., Facial nerve dysfunction after parotidectomy: the role of local factors. The Laryngoscope, 2005. 115(2): p. 287-91.
[177] Eng, C.Y., et al., A comparison of the incidence of facial palsy following parotidectomy performed by ENT and non-ENT surgeons. The Journal of laryngology and otology, 2007. 121(1): p. 40-3.
[178] Roh, J.L. and C.I. Park, A prospective, randomized trial for use of prednisolone in patients with facial nerve paralysis after parotidectomy. American journal of surgery, 2008. 196(5): p. 746-50.
[179] Klintworth, N., et al., Postoperative complications after extracapsular dissection of benign parotid lesions with particular reference to facial nerve function. The Laryngoscope, 2010. 120(3): p. 484-90.
[180] Mahmood, K., G.S. Williams, and N. Morgan, Postparotidectomy facial nerve paralysis: peripheral versus proximal identification. B-ENT, 2010. 6(2): p. 117-21.
[181] Fitzpatrick, P.J. and C. Theriault, Malignant salivary gland tumors. International journal of radiation oncology, biology, physics, 1986. 12(10): p. 1743-7.
[182] Tran, L., et al., Major salivary gland tumors: treatment results and prognostic factors. The Laryngoscope, 1986. 96(10): p. 1139-44.
[183] Frankenthaler, R.A., et al., Prognostic variables in parotid gland cancer. Archives of otolaryngology--head & neck surgery, 1991. 117(11): p. 1251-6.
[184] Mendenhall, W.M., et al., Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head & neck, 2004. 26(2): p. 154-62.
[185] Pohar, S., et al., Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. International journal of radiation oncology, biology, physics, 2005. 61(1): p. 112-8.
[186] Chen, A.M., et al., Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. International journal of radiation oncology, biology, physics, 2006. 66(1): p. 152-9.
Cite This Article
  • APA Style

    Rodrigo Arrangoiz, Pavlos Papavasiliuo, David Sarcu, Thomas J. Galloway, John A. Ridge, et al. (2013). Current Thinking on Malignant Salivary Gland Neoplasms. Journal of Cancer Treatment and Research, 1(1), 8-24. https://doi.org/10.11648/j.jctr.20130101.12

    Copy | Download

    ACS Style

    Rodrigo Arrangoiz; Pavlos Papavasiliuo; David Sarcu; Thomas J. Galloway; John A. Ridge, et al. Current Thinking on Malignant Salivary Gland Neoplasms. J. Cancer Treat. Res. 2013, 1(1), 8-24. doi: 10.11648/j.jctr.20130101.12

    Copy | Download

    AMA Style

    Rodrigo Arrangoiz, Pavlos Papavasiliuo, David Sarcu, Thomas J. Galloway, John A. Ridge, et al. Current Thinking on Malignant Salivary Gland Neoplasms. J Cancer Treat Res. 2013;1(1):8-24. doi: 10.11648/j.jctr.20130101.12

    Copy | Download

  • @article{10.11648/j.jctr.20130101.12,
      author = {Rodrigo Arrangoiz and Pavlos Papavasiliuo and David Sarcu and Thomas J. Galloway and John A. Ridge and Miriam Lango},
      title = {Current Thinking on Malignant Salivary Gland Neoplasms},
      journal = {Journal of Cancer Treatment and Research},
      volume = {1},
      number = {1},
      pages = {8-24},
      doi = {10.11648/j.jctr.20130101.12},
      url = {https://doi.org/10.11648/j.jctr.20130101.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20130101.12},
      abstract = {Malignant salivary gland neoplasms are rare, representing approximately 3% to 7% of all head and neck cancers. Contrasting from the more common mucosal head and neck cancers, which, in general, are ascribed to excessive tobacco, alcohol use, and more recently to viral infection, specific carcinogenic factors for malignant salivary gland growths have not been as clearly identified. Histologically, they represent a heterogeneous group of tumors. Forty histologic types of epithelial tumors of the salivary glands have been reported; some are exceedingly rare and may be the topic of only a few case reports. Salivary tumors can arise in the major salivary glands or in one of the minor salivary glands (predominantly mucus secreting glands), which are distributed throughout the upper aerodigestive. Most patients who develop malignant salivary gland tumors are in the sixth or seventh decade of life. FNA should be considered as part of the diagnostic evaluation but due to its varying sensitivities and specificities imaging modalities such as ultrasound, CT scans, and MRI should also be used as diagnostic adjuncts. Surgery is the primary modality for management of these tumors, nontraditional surgical approaches and instrumentation, as well as facial nerve monitoring, can be selectively utilized to try and decrease the morbidity associated with these surgical procedures. Adjuvant treatment is primarily achieved with radiation therapy. Chemotherapy continues to have a palliative role in the management of salivary gland tumors; however, research in this field is trying to identify a therapeutic role for chemotherapy in order to improve overall survival.},
     year = {2013}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Current Thinking on Malignant Salivary Gland Neoplasms
    AU  - Rodrigo Arrangoiz
    AU  - Pavlos Papavasiliuo
    AU  - David Sarcu
    AU  - Thomas J. Galloway
    AU  - John A. Ridge
    AU  - Miriam Lango
    Y1  - 2013/08/10
    PY  - 2013
    N1  - https://doi.org/10.11648/j.jctr.20130101.12
    DO  - 10.11648/j.jctr.20130101.12
    T2  - Journal of Cancer Treatment and Research
    JF  - Journal of Cancer Treatment and Research
    JO  - Journal of Cancer Treatment and Research
    SP  - 8
    EP  - 24
    PB  - Science Publishing Group
    SN  - 2376-7790
    UR  - https://doi.org/10.11648/j.jctr.20130101.12
    AB  - Malignant salivary gland neoplasms are rare, representing approximately 3% to 7% of all head and neck cancers. Contrasting from the more common mucosal head and neck cancers, which, in general, are ascribed to excessive tobacco, alcohol use, and more recently to viral infection, specific carcinogenic factors for malignant salivary gland growths have not been as clearly identified. Histologically, they represent a heterogeneous group of tumors. Forty histologic types of epithelial tumors of the salivary glands have been reported; some are exceedingly rare and may be the topic of only a few case reports. Salivary tumors can arise in the major salivary glands or in one of the minor salivary glands (predominantly mucus secreting glands), which are distributed throughout the upper aerodigestive. Most patients who develop malignant salivary gland tumors are in the sixth or seventh decade of life. FNA should be considered as part of the diagnostic evaluation but due to its varying sensitivities and specificities imaging modalities such as ultrasound, CT scans, and MRI should also be used as diagnostic adjuncts. Surgery is the primary modality for management of these tumors, nontraditional surgical approaches and instrumentation, as well as facial nerve monitoring, can be selectively utilized to try and decrease the morbidity associated with these surgical procedures. Adjuvant treatment is primarily achieved with radiation therapy. Chemotherapy continues to have a palliative role in the management of salivary gland tumors; however, research in this field is trying to identify a therapeutic role for chemotherapy in order to improve overall survival.
    VL  - 1
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Temple University, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia USA 19111

  • Temple University, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia USA 19111

  • Temple University, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia USA 19111

  • Temple University, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia USA 19111

  • Temple University, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia USA 19111

  • Temple University, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia USA 19111

  • Sections